CPP (Cancer Prevention Pharmaceuticals) ROCE % : 0.00% (As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cancer Prevention Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2016 was 0.00%.

Cancer Prevention Pharmaceuticals ROCE % Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals ROCE % Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

ROCE %

-439.06

-494.75

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
ROCE %	Get a 7-Day Free Trial			-379.74	-367.54	-	-	-

Cancer Prevention Pharmaceuticals ROCE % Calculation

Cancer Prevention Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2015 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2015 )		(A: Dec. 2014 )		(A: Dec. 2015 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2015 )		(A: Dec. 2014 )		(A: Dec. 2015 )
	=	-3.923	/	( ( (4.86 - 3.221)	+	(1.85 - 5.927) )	/ 2 )
	=	-3.923	/	( (1.639	+	-4.077)	/ 2 )
	=	-3.923	/	-1.219
	=	321.82 %

Cancer Prevention Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2016 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2016 )		(Q: Dec. 2015 )		(Q: Mar. 2016 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2016 )		(Q: Dec. 2015 )		(Q: Mar. 2016 )
	=	-8.512	/	( ( (1.85 - 5.927)	+	(9.189 - 9.396) )	/ 2 )
	=	-8.512	/	( ( -4.077	+	-0.207 )	/ 2 )
	=	-8.512	/	-2.142
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2016) EBIT data.

Cancer Prevention Pharmaceuticals (AMEX:CPP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cancer Prevention Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.